RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FICORELLA C
Collezione AOU Città della Salute di Torino

Items : 8

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

2022
ASL Torino 4
AOU Città della Salute di Torino

Ferri C; Parisi A; Ficorella C; Cortellini A; Pensieri MV; Aimar G; Roberto M; Petrillo A; Zoratto F; Spinelli GP; Garajova I; Vitale P; Zanaletti N; De Tursi M; Di Pietro FR; Morelli C; Giampieri R; Depetris I; Keränen SR; Lombardi P; Zurlo IV; Dell'Aquila E; Gelsomino F; Ghidini M; Nigro O; Filippi R; Salvatore L; Porzio G; Fargnoli MC; et alii...

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

D'Orazio C; Ficorella C; Petrillo A; Ierino D; Spinelli GP; Roberto M; Zoratto F; Ghidini M; Vitale P; Garajova I; Troiani T; Di Pietro FR; De Galitiis F; Zanaletti N; Tinari N; Morelli C; Giampieri R; De Tursi M; Aimar G; Depetris I; Lombardi P; Keränen SR; Claudia F; Leo S; Dell'Aquila E; Spallanzani A; Zurlo V; Gelsomino F; Nigro O; et alii...

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. in Frontiers in oncology / Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.

2021
ASL Torino 4
AOU Città della Salute di Torino

Porzio G; Ficorella C; Ferri C; D'Orazio C; Patruno L; Petrillo A; Aimar G; Zoratto F; Roberto M; Spinelli GP; Garajova I; Vitale P; Zanaletti N; Morelli C; Di Marino P; Di Pietro FR; Depetris I; Giampieri R; Roselló Keränen S; Fulgenzi C; Lombardi P; Zurlo IV; Gelsomino F; Nigro O; Ghidini M; Tortora G; Salvatore L; Filippi R; Venditti O; et alii...

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.

2020
AOU Città della Salute di Torino

Biganzoli L; Donadio M; Giordano M; Clivio L; Scavelli C; Frassoldati A; Palumbo R; Ferzi A; Schirone A; Gebbia V; Fabi A; Santini D; Porpiglia M; Turletti A; Atzori F; De Laurentiis M; Blasi L; Artale S; Bianchi GV; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; et alii...

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Fabi A; Cursano MC; Benedetto C; Turletti A; Atzori F; Piezzo M; Artale S; Blasi L; Bianchi G; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; Diodati L; Arcangeli V; Ficorella C; Moretti G; Airoldi M; Sartori D; Valerio MR; Fumagalli A; Ciccarese M; Verusio C; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Cursano MC; Benedetto C; Turletti A; Atzori F; Piezzo M; Blasi L; Artale S; Bianchi G; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; Diodati L; Arcangeli V; Ficorella C; Moretti G; Airoldi M; Ancona C; Valerio MR; Sartori D; Fumagalli A; Ciccarese M; Verusio C; et alii...

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

2017
ASL Città di Torino
AOU Città della Salute di Torino

Sartori D; Scavelli C; Porpiglia M; Pistelli M; Palumbo R; Musolino A; Moretti G; Michelotti A; Maur M; La Verde N; Generali D; Gebbia V; Garrone O; Frassoldati A; Fumagalli A; Ficorella C; Ferzi A; Ferrari L; Fabi A; Piezzo M; Cursano MC; Ciccarese M; Campidoglio S; Blasi L; Bianchi GV; Ballerio A; Atzori F; Artale S; Arcangeli V; et alii...